Synopsis A novel clinical trial for the Study Of diabetic Nephropathy with Atrasentan to test the possible renoprotective effects of the Endothelin receptor antagonist (ERA), atrasentan in patients at high risk of progressing to end stage renal disease (ESRD). This week's 'MED FACT' discusses a clinical trial from Diabetes, Obesity and Metabolism, “ Rationale and protocol of the Study Of diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy ”. June 2018.
Authors : Heerspink HJ; Andress DL; Bakris G; Brennan JJ; Correa‐Rotter R; Dey J; Hou FF; Kitzman DW; Kohan D; Makino H; McMurray J. Key Takeaways 51% of participants receiving atrasentan 0.75 mg/day achieved a ≥30% reduction in urinary albumin to creatinine ratio (UACR) Objective Study Type Participants To analyse the effect of Atrasentan on renal outcomes in the study Of diabetic…
